U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07146347) titled 'Comparison Study of Insulin GZR4 With Insulin Degludec' on Aug. 18.
Brief Summary: In this study, the investigational product will be compared with insulin degludec (Tresiba(R)) and insulin icodec (Awiqli(R)). The comparator products are approved for the treatment of T2DM in the European Union.
Study Start Date: Aug. 15
Study Type: INTERVENTIONAL
Condition:
Type 2 Diabetes
Intervention:
DRUG: GZR4 injection
GZR4 is a new ultra-long-acting insulin analog
Recruitment Status: RECRUITING
Sponsor: Gan and Lee Pharmaceuticals, USA
Published by HT Digital Content Services with permission from Health Daily Digest....